Making a ton of money
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Got a few my man How do you like the way this all played out. Told ya so.
ya think
Looking strong into the close .23 x .24 +.03
Right on mark for our 10 day avg. volume. Time for a push upward. 250k daily 10 day avg.
0.21
Market Cap ($)
28.7M
Today's Open
0.22
Shares Out.
119.8M
Day's Range
0.22 - 0.245
EPS
-0.68
Avg Vol (10-day)
248.1K
P/E Ratio
--
Last (time)
3:16p ET 02/24/09
Dividend/Yield
No Regular Dividends
Last (size)
100
Ex-Dividend Date
--
52wk Range
0.15 - 8.26
Beta
1.2
60% above its low
12/19/08 - 02/27/08
% Held by Inst
40.56
Implied Volatility
290.0%
Short Interest (% of float)
9.04
Historical Volatility
167.2%
Historical Quotes & Splits
Very good. Back to reality now everyone. Be careful with whom you listen to. Glta
I would think we would get some type of update soon. Good Luck
Go back to post 795 and look at the Relative Strength Index now.
She is ready to go!!!!!!!!!!!!!!!!!!!
Getting some of that hard earned money back. Do we have a buyer
of the shell?
This bad boy is moving.
Lot of volume coming in up 40% this morning. Moving up nicely.
Whats UPPPPPPPPPP!!!!!!!!!
Good morning all how about a little run today. GLTA
We had the 50 DMA cross over the 100 DMA in the last couple days of trading. Using Crossovers isn't quite as easy as filtering. There are several different types of crossover's, but all of them involve two or more moving averages. In a double crossover you are looking for a situation where the shortest MA crosses through the longer one. This is almost always considered to be a buying signal since the longer average is somewhat of a support level for the stock price.
RSI approaching 50, bullish territory. Look for a great day today. GLTA
That was a decent close.. Did you see seconds and I mean maybe a second after close it went to .29 on the ask. We are close.
See ya in the a.m.
Looked like +.02 Not a bad close. See ya all in the a.m.
Volume coming in let's close strong and set up the charts for next leg up. GLTA
Yes nice bid support this morning. How bout a little update from the company and get this baby moving upward. GLTA
A little pre-market activity + .02 Have a great day all.
We have a news update!!!!
MDRNA Successfully Silences Gene Targets in Animal Models Using Novel UsiRNA Constructs
Proprietary DiLA2 Platform Achieves In Vivo Knockdown of Multiple Metabolic Targets and Demonstrates Safe and Effective Delivery in Repeat Dose Studies
* Monday February 23, 2009, 8:30 am EST
Related:
* MDRNA, Inc.
BOTHELL, WA--(MARKET WIRE)--Feb 23, 2009 -- MDRNA, Inc. (NasdaqGM:MRNA - News) announced today positive in vivo efficacy data on its proprietary UsiRNA constructs demonstrating a dose response which resulted in up to 90% knockdown of ApoB message in a rodent model. The data were presented by Michael V. Templin, Ph.D., Vice President, Discovery Research and Pharmaceutical Development of MDRNA, at the inaugural Informa Life Sciences TIDES Oligonucleotide and Peptide® Research, Technology and Product Development Conference in Tokyo, Japan.
Related Quotes
Symbol Price Change
MRNA 0.2799 0.0000
Chart for MDRNA, Inc.
{"s" : "mrna","k" : "c10,l10,p20,t10","o" : "","j" : ""}
"Our UsiRNA constructs offer a novel and proprietary means of providing highly potent siRNAs while increasing specificity," stated Barry Polisky, Ph.D., Chief Scientific Officer of MDRNA. "UsiRNAs were highly active in the mouse ApoB model for both message inhibition and serum cholesterol reduction. In these cases, UsiRNAs were fully compatible with RNAi machinery yet showed a substantial decrease in cytokine response. We are encouraged by these significant results and believe we have a unique siRNA construct to silence genes while minimizing potential side effects."
UsiRNAs are duplex siRNAs that are modified with non-nucleotide acyclic monomers, termed unlocked nucleobase analogs (UNA), in which the bond between two adjacent carbon atoms of ribose is removed. UsiRNAs are fully recognized by the RNAi machinery and provide for potent RNAi activity. Placement of UNA within UsiRNA minimizes the potential for off-target effects by the guide strand as well as undesired activity of the passenger strand. Further, the change in sugar structure renders this unlocked nucleobase analog conformationally flexible. The flexibility of the monomer escapes the surveillance mechanisms associated with cytokine induction, as well as providing protection from nuclease degradation.
MDRNA also reported new information on its DiLA2 Platform delivery technology:
"We are pleased to announce that our proprietary DiLA2 Platform achieved knockdown of two additional genes in liver tissue, DGAT2 and PCSK9, that are potentially important therapeutic targets, and the Platform continues to demonstrate safe and effective delivery following repeat systemic dosing of up to 9 mg/kg of siRNA formulations in mice," added Dr. Polisky. "The acute and repeat dose tolerability data of the DiLA2 Platform are promising. Repeat dosing on an every-third-day schedule for two weeks further indicates that DiLA2 liposomes are well tolerated. Our ability to deliver siRNAs to hepatocytes while achieving knockdown of multiple gene targets affirms our belief that the DiLA2 Platform represents a significant advancement in the development of a novel formulation for improved siRNA delivery."
"Our proprietary and novel UsiRNA constructs -- highly active siRNAs which minimize off-target activity -- represent a potential major step forward in the development of RNAi-based therapeutics," stated J. Michael French, President and Chief Executive Officer of MDRNA. "Further, our DiLA2 Platform continues to demonstrate its versatility in its ability to safely and efficiently deliver siRNAs against multiple gene targets and effectively silence those genes. The results reported today represent a further demonstration of the breadth and depth of our RNAi-based drug discovery engine and the capability and expertise of our scientific team."
About the DiLA2 Platform
The DiLA2 Platform is MDRNA's proprietary platform for creating novel liposomal delivery systems from amino acids. The platform enables MDRNA to tailor the charge, linker and acyl chains of amino acids in order to optimize the liposome for delivery to the target tissue of interest. In addition, the platform is designed to permit attachment of various peptides and other targeting molecules to improve a variety of delivery characteristics. In addition, MDRNA is utilizing peptides for nanoparticle formulations to increase cellular uptake and endosomal release.
About MDRNA, Inc.
MDRNA is a biotechnology company focused on the development and commercialization of therapeutic products based on RNA interference (RNAi). Our goal is to improve human health by combining novel RNAi-based compounds and proprietary peptide- and liposomal-based drug delivery technologies to provide superior therapeutic options. Our multi-disciplinary portfolio of capabilities includes molecular biology, cellular biology, formulation expertise, peptide and alkylated amino acid chemistry, pharmacology, toxicology and bioinformatics. We are applying this expertise to a single, integrated drug discovery platform that will be the engine for our clinical pipeline and a versatile platform for establishing broad therapeutic partnerships. We are also building on new technologies, such as UsiRNAs that incorporate the non-nucleotide moiety Unlocked Nucleobase Analog (UNA) within the siRNA molecule, that we expect to lead to safer and more effective RNAi-based therapeutics. By combining broad expertise in siRNA science with proven delivery platforms and a strong and growing IP position, MDRNA is well positioned as a leading RNAi therapeutics company and value-added collaborator for our research partners. Additional information about MDRNA, Inc. is available at http://www.mdrnainc.com.
MDRNA Forward-Looking Statement
Statements made in this news release may be forward-looking statements within the meaning of Federal Securities laws that are subject to certain risks and uncertainties and involve factors that may cause actual results to differ materially from those projected or suggested. Factors that could cause actual results to differ materially from those in forward-looking statements include, but are not limited to: (i) the ability of MDRNA or a subsidiary to obtain additional funding; (ii) the ability of MDRNA or a subsidiary to attract and/or maintain manufacturing, research, development and commercialization partners; (iii) the ability of MDRNA, a subsidiary and/or a partner to successfully complete product research and development, including preclinical and clinical studies and commercialization; (iv) the ability of MDRNA, a subsidiary and/or a partner to obtain required governmental approvals; and (v) the ability of MDRNA, a subsidiary and/or a partner to develop and commercialize products that can compete favorably with those of competitors. Additional factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statements are contained in MDRNA's most recent periodic reports on Form 10-K and Form 10-Q that are filed with the Securities and Exchange Commission. MDRNA assumes no obligation to update and supplement forward-looking statements because of subsequent events.
200 shares at .44 Let it rip from here
Looking good this morning. Nice buys on the ask. GLTY
Level 2 is very active this morning. Bid is building. Have a great day all
No fill for balance of .23 will try in a.m. Maybe if they wait
long enough I will be in the teens. Hope not See ya in a.m.
NO fill yet at .23 looks like there not any left jumping to .24
then back to .22 this is strange????????????????
I will try again before the close but I bet you are right watch all the volume into the close
Spoke to advisor some type of electronic feed is temp. down they said I could cancel and re submit but not guarantees today.
I said I had a partial fill and of course sorry sir this is beyond our control. Go figure.
Exactly just when you start to get a little buying pressure they hold for after hours. ??????????
This also happened yesterday going into the close at .24 Hang on to your hats here crew.
Still nothing on my .23 I will be calling TDA within a few minutes
I have about 5000 shares at .23 that haven't filled yet ????
Already got some at .23
very tight spread I don't believe they can hold it down into close I have a few thousand to throw at it. Looking strong EOD
Looking pretty thin to .25 if we can get some volume IMO
Nice bid support this a.m. she may be ready to move northbound.
GLTA
You are right. Maybe we get a little pop this morning. GLTA
Picked up a few more at .24 yesterday. Seems like they were never ending. Let's move up today. GLTA
We were not the only ones that had a down day yesterday. I believe today if the markets turn around a bit we should start moving northward again. GLTA
Tuesday, February 17, 2009, 2:33pm PST
OncoGenex leads state stock slide
Puget Sound Business Journal (Seattle)
Led by OncoGenex Pharmaceuticals Inc., with its shares plummeting nearly 27 percent in Tuesday trading, nearly all Washington state companies traded on the NASDAQ and New York Stock Exchange saw shares fall.
Of the nearly 100 Washington public companies traded on the two major exchanges, only six rose in price Tuesday.
Led by OncoGenex (NASDAQ: OGXI) of Bothell, which fell $1.05 to close at $2.90, other big droppers in the state included Nautilus Inc. (NYSE: NLS) of Vancouver, Wash., which fell 24 cents, or 26.37 percent, to close at 67 cents; biotech MDRNA Inc. (NASDAQ: MRNA) of Bothell, which fell 11 cents, or 25.58 percent, to close at 32 cents; and Frontier Financial Corp. (NASDAQ: FTBK) of Everett, which fell 35 cents, or 18.32 percent, to close at $1.56.
Registering surprising advances on Tuesday were AmericanWest Bancorporation (NASDAQ: AWBC) of Spokane, which rose 3 cents, or 6.67 percent, to close at 48 cents and Flow International Corp. (NASDAQ: FLOW) of Kent, which rose 6 cents, or 4.51 percent, to close at $1.39.
Thanks for the charts. Hope everyone had a nice break from trading over the long weekend. Hopefully the word is spreading on the latest news over the past few days on MRNA. What kind of reaction do you think we will get out of the gate in the a.m.
With the large volume on Friday and the way the charts are looking the stock should be sounding out to a new crowd of investors. GLTA
Up 72% today. We will take it. Have a great extended weekend all.
Lot of movement by m m's must be getting close. GLTY